Our evaluation framework is based on the internationally accepted evaluation framework of the Organization for Economic Co-operation and Development’s Development Assistance Committee, including its principles and criteria for grant evaluations. The framework was updated in 2022 to align with our 2023-2027 Strategy.

We require at least one evaluation for each investment or portfolio of investments, typically conducted within 12 months of closure. We also conduct prospective evaluations to facilitate real-time learning and thematic evaluations to review performance and capture learning within cross-cutting areas of our strategic framework.

Upcoming evaluations

1. Portfolio Evaluation: Better tools for diagnosis and treatment of drug-resistant tuberculosis (Ref. link: RFP 2024.14 Portfolio Evaluation: Better tools for diagnosis and treatment of drug-resistant tuberculosis)
2. Mid-Term Review of Unitaid’s 2023-2027 Strategy (Ref. link: RFP 2024.16 Mid-Term Review of Unitaid’s 2023-2027 Strategy)
3. Review of Unitaid’s scalability approach: challenges and opportunities (Ref. link: RFP 2024.17 Review of Unitaid’s scalability approach: challenges and opportunities)
4. End-of-Grant Evaluation – Medicines Patent Pool (MPP III), (Ref. link: https://www.ungm.org/Public/Notice/257052)